• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

度普利尤单抗的真实世界副作用:一项叙述性综述。

Real World Side-Effects of Dupilumab: A Narrative Review.

作者信息

Larney Conor, Foley Peter, Wu Jason, Daniel Benjamin S

机构信息

Department of Dermatology, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.

Skin Health Institute, Carlton, Victoria, Australia.

出版信息

Australas J Dermatol. 2025 Sep;66(6):e324-e334. doi: 10.1111/ajd.14557. Epub 2025 Jun 25.

DOI:10.1111/ajd.14557
PMID:40557973
Abstract

Real-world use of dupilumab has unveiled a spectrum of side effects that were not fully appreciated in initial clinical trials. While dupilumab remains a highly effective treatment for atopic dermatitis, clinicians must be aware of real-world adverse effects including ocular complications, inflammatory arthritis, psoriasiform eruptions and head and neck dermatitis; as well as reported associations including cutaneous T-cell lymphoma, alopecia areata, vitiligo and weight gain.

摘要

度普利尤单抗在现实世界中的应用揭示了一系列在最初临床试验中未被充分认识到的副作用。虽然度普利尤单抗仍然是治疗特应性皮炎的高效药物,但临床医生必须了解现实世界中的不良反应,包括眼部并发症、炎性关节炎、银屑病样皮疹和头颈部皮炎;以及已报道的关联,包括皮肤T细胞淋巴瘤、斑秃、白癜风和体重增加。

相似文献

1
Real World Side-Effects of Dupilumab: A Narrative Review.度普利尤单抗的真实世界副作用:一项叙述性综述。
Australas J Dermatol. 2025 Sep;66(6):e324-e334. doi: 10.1111/ajd.14557. Epub 2025 Jun 25.
2
Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.度普利尤单抗治疗成人特应性皮炎合并结膜炎:一项关于临床特征、症状学及治疗的观察性研究
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03209-4.
3
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.乌帕替尼与度普利尤单抗治疗四个身体部位中重度特应性皮炎的疗效和安全性:来自Heads Up研究的分析
Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30.
4
Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.特应性皮炎患者度普利尤单抗眼部不良反应:系统评价。
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):820-835. doi: 10.1111/jdv.17981. Epub 2022 Feb 17.
5
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
6
Ocular surface evaluation in atopic dermatitis patients on dupilumab: A prospective observational study.度普利尤单抗治疗特应性皮炎患者的眼表评估:一项前瞻性观察研究。
J Fr Ophtalmol. 2025 Jun;48(6):104544. doi: 10.1016/j.jfo.2025.104544. Epub 2025 May 8.
7
Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis.特应性皮炎患者接受度普利尤单抗治疗后斑秃复发。
Dermatitis. 2021 Oct 1;32(1S):e80-e82. doi: 10.1097/DER.0000000000000512.
8
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中,度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
9
Maternal, Fetal, and Labour Outcomes of Dupilumab Use for Atopic Dermatitis During Pregnancy: A Systematic Review.孕期使用度普利尤单抗治疗特应性皮炎的母体、胎儿及分娩结局:一项系统评价
J Cutan Med Surg. 2025 Jan-Feb;29(1):51-55. doi: 10.1177/12034754241290806. Epub 2024 Oct 20.
10
Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials.特应性皮炎患者接受度普利尤单抗治疗的感染风险:一项随机对照试验的荟萃分析。
J Am Acad Dermatol. 2018 Jan;78(1):62-69.e1. doi: 10.1016/j.jaad.2017.09.052. Epub 2017 Oct 4.